Author: ithero

Satoria Pharma, a newcomer in the Pharmaceutical Industry, is currently producing IV solutions and its bottles with capacity of 50 million bottles/year to serve Indonesian local markets. The new expansion will enlarge its capacity by 70 – 110 Million bottles/year, and is targeted to materialize in early 2019.

“Our expansion is an effort to anticipate the sharp rise in the needs of IV solutions in the coming years due to Indonesian President’s – President Joko Widodo’s effort to implement BPJS Programme (the Indonesian National Health Insurance System) nationwide.” Affirmed Mr. Alim Satria, CEO and Founder of Satoria Pharma.

In the pipeline, Satoria Pharma is planning to further expand into various healthcare sectors, such as: Hemodyalysis Fluid, Dialysis Machine, Vacuum Blood Tubing System, Patient Monitor, etc. Total investment is estimated to reach USD 18 Million and the programme is targeted to complete in the next 1-2 years from now.

Satoria Pharma hopes to support the Indonesian Government’s “Total Health Coverage” Progamme to bring better health to the Nation. In a market dominated with foreign investors, Satoria Pharma wishes to see that Indonesia becomes a country independent from other countries to fulfill its healthcare needs.

Satoria Pharma’s 4 IV Solution Products – Ringer Lactate, Sodium Chloride 0.9%, Dextrose 5% and Dextrose 10% are officially listed in the Indonesian Government’s LPSE E Catalogue website. Government hospitals across the Nation are able to purchase our products through the E Purchasing Platform.

Satoria Pharma also serves privately-owned hospitals not purchasing through the E Catalogue system and offers its branded products “Inochi” to prestigious hospitals in Indonesia.

With production capacity of 50 Million bottles/year, Satoria Pharma is the only 100% Indonesian Investment Pharmaceutical Company to be awarded in this biennial Government Tender process.